SARS-CoV-2 Multi-Antigen Serology Assay

Mazhari, Ramin; Ruybal‐Pesántez, Shazia; Angrisano, Fiona; Kiernan-Walker, Nicholas; Hyslop, Stephanie; Longley, Rhea J.; Bourke, Caitlin; Chen, Catherine; Williamson, Deborah A; Robinson, Leanne J.; Müeller, Ivo; Eriksson, Emily M.

doi:10.3390/mps4040072

Cited by 5 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RT‐PCR lacks information on the infectious nature and host–pathogen interactions and cannot distinguish between viable and nonviable virus (Y. Chen et al, 2022 ; Healy et al, 2021 ). Alternative approaches to diagnose and test for SARS‐CoV‐2 include epitope mapping, enzyme‐linked immunoassays, and multi‐antigen serology assays (Haynes et al, 2021 ; Mazhari et al, 2021 ; Noy‐Porat et al, 2020 ; Roy et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Proteomics‐based mass spectrometry profiling of SARS‐CoV‐2 infection from human nasopharyngeal samples

Chatterjee

Zaia

2022

Mass Spectrometry Reviews

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is the cause of the on‐going global pandemic of coronavirus disease 2019 (COVID‐19) that continues to pose a significant threat to public health worldwide. SARS‐CoV‐2 encodes four structural proteins namely membrane, nucleocapsid, spike, and envelope proteins that play essential roles in viral entry, fusion, and attachment to the host cell. Extensively glycosylated spike protein efficiently binds to the host angiotensin‐converting enzyme 2 initiating viral entry and pathogenesis. Reverse transcriptase polymerase chain reaction on nasopharyngeal swab is the preferred method of sample collection and viral detection because it is a rapid, specific, and high‐throughput technique. Alternate strategies such as proteomics and glycoproteomics‐based mass spectrometry enable a more detailed and holistic view of the viral proteins and host–pathogen interactions and help in detection of potential disease markers. In this review, we highlight the use of mass spectrometry methods to profile the SARS‐CoV‐2 proteome from clinical nasopharyngeal swab samples. We also highlight the necessity for a comprehensive glycoproteomics mapping of SARS‐CoV‐2 from biological complex matrices to identify potential COVID‐19 markers.

show abstract

Section: Introductionmentioning

confidence: 99%

Proteomics‐based mass spectrometry profiling of SARS‐CoV‐2 infection from human nasopharyngeal samples

Chatterjee

Zaia

2022

Mass Spectrometry Reviews

View full text Add to dashboard Cite

show abstract

“…A pool of SARS‐CoV‐2–positive patients and a negative control are included on each plate. All other steps are as described 17 . Cut‐off values were calculated using the mean + 3 standard deviations of the negative cohort.…”

Section: Methodsmentioning

confidence: 99%

“…The MBA described in Mazhari et al 17 was used with the following amendments. Prior to the addition of antigencoupled beads, the plasma was incubated with CSC reagent at a concentration of 4 lg mL À1 in PBT (1% bovine serum albumin 19 phosphate-buffered saline + 0.05% Tween 20 (all items from Sigma, St Louis, Missouri, USA) for 2 h at room temperature.…”

Section: Mbamentioning

confidence: 99%

Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infections

Wei,

Angrisano,

Eriksson

et al. 2023

Immunol Cell Biol

Self Cite

View full text Add to dashboard Cite

Current serological tests cannot differentiate between total immunoglobulin A (IgA) and dimeric IgA (dIgA) associated with mucosal immunity. Here, we describe two new assays, dIgA‐ELISA and dIgA‐multiplex bead assay (MBA), that utilize the preferential binding of dIgA to a chimeric form of secretory component, allowing the differentiation between dIgA and monomeric IgA. dIgA responses elicited through severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection were measured in (i) a longitudinal panel, consisting of 74 samples (n = 20 individuals) from hospitalized cases of coronavirus disease 2019 (COVID‐19); (ii) a longitudinal panel, consisting of 96 samples (n = 10 individuals) from individuals with mild COVID‐19; (iii) a cross‐sectional panel with PCR‐confirmed SARS‐CoV‐2 infection with mild COVID‐19 (n = 199) and (iv) pre–COVID‐19 samples (n = 200). The dIgA‐ELISA and dIgA‐MBA demonstrated a specificity for dIgA of 99% and 98.5%, respectively. Analysis of dIgA responses in the longitudinal panels revealed that 70% (ELISA) and 50% (MBA) of patients elicited a dIgA response by day 20 after PCR diagnosis with a SARS‐CoV‐2 infection. Individuals with mild COVID‐19 displayed increased levels of dIgA within the first 3 weeks after diagnosis but responses appeared to be short lived, compared with sustained IgA levels. However, in samples from hospitalized patients with COVID‐19 we observed high and sustained levels of dIgA, up to 245 days after PCR diagnosis. Our results suggest that severe COVID‐19 infections are associated with sustained levels of plasma dIgA compared with mild cases.

show abstract

“…To establish the serostatus of participants, SARS-CoV-2-specific IgG antibodies were measured at baseline for all participants using a Luminex multiplex assay (7). This assay measures antibodies that recognize and bind to full-length Spike, receptorbinding domain (RBD), S1, S2 and nucleoprotein, all based on the Wuhan variant sequence.…”

Section: Findings To Datementioning

confidence: 99%

Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID PROFILE)

Eriksson

Hart

Forde

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: The COVID PROFILE cohort is a longitudinal clinical study based in Victoria Australia, which was established to understand immunity to SARS-CoV-2 in a low transmission population setting and to identify immunological markers of long-term immunity and immune-dysregulation after both infection and vaccination. Additionally, this cohort was established as a biobank resource for researchers to address other health-related immunological questions. Participants: We enrolled 178 adult community members, including household contacts, who had either recovered from a SARS-CoV-2 infection or were SARS-CoV-2 naive. Only participants 18 years of age or older and, in the case of female participants, non-pregnant women at the time of enrollment were included in the study. Detailed COVID-19 clinical data, vaccination status, medical history and demographics was collected. Findings to date: At enrollment, we found that 87.8% of COVID-19 recovered individuals were seropositive with detectable levels of anti-SARS-CoV-2 IgG antibodies. Seronegative COVID-19 recovered individuals included asymptomatic individuals or participants that were enrolled more than 12 months after their COVID-19 diagnosis. Except for one individual who was seropositive at baseline despite a previous SARS-CoV-2 PCR negative diagnosis, all household contacts and other community members enrolled as SARS-CoV-2 PCR negative, were seronegative for all SARS-CoV-2-specific antibodies tested. The infection rate (re-infection or new infection) during 24 months of the study was 42.7%, as determined by either rapid antigen tests, PCRs or serology screens. Of the SARS-CoV-2 recovered participants, 32.6% reported ongoing symptoms at enrollment of which 47% had already experienced ongoing symptoms for more than 12 weeks. Future Plans: COVID PROFILE will be used to comprehensively understand temporal immunity to SARS-CoV-2 and COVID-19 vaccines and to understand the impact of host immunological composition on such immunity and symptom severity. Additionally, studies focusing on understanding immunity following breakthrough infections and immunological risk factors that contribute towards development of long COVID are planned.

show abstract

SARS-CoV-2 Multi-Antigen Serology Assay

Cited by 5 publications

References 26 publications

Proteomics‐based mass spectrometry profiling of SARS‐CoV‐2 infection from human nasopharyngeal samples

Proteomics‐based mass spectrometry profiling of SARS‐CoV‐2 infection from human nasopharyngeal samples

Serological assays to measure dimeric IgA antibodies in SARS‐CoV‐2 infections

Cohort Profile: A longitudinal Victorian COVID-19 cohort (COVID PROFILE)

Contact Info

Product

Resources

About